RBC Capital analyst Conor McNamara maintains $Maravai LifeSciences (MRVI.US)$ with a buy rating, and adjusts the target price from $17 to $13.
According to TipRanks data, the analyst has a success rate of 38.4% and a total average return of -7.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Maravai LifeSciences (MRVI.US)$'s main analysts recently are as follows:
Maravai Lifesciences reported a Q3 loss wider than anticipated. This comes after consistent solid performance in comparison to guidance across three consecutive quarters. The company has been impacted by the challenging biotech spending landscape and the irregular order patterns from customers that are characteristic of their sector.
Maravai Lifesciences' third-quarter results fell short of expectations, with performance lagging in both segments compared to projections. The company indicated a decline in research/discovery demand, an absence of significant drop-in orders, and a postponement of several GMP program timings into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇资本市场分析师Conor McNamara维持$Maravai LifeSciences (MRVI.US)$买入评级，并将目标价从17美元下调至13美元。
根据TipRanks数据显示，该分析师近一年总胜率为38.4%，总平均回报率为-7.3%。
此外，综合报道，$Maravai LifeSciences (MRVI.US)$近期主要分析师观点如下：
Maravai Lifesciences报告称，第三季度的亏损超出预期。这是在连续三个季度的预期表现持续稳健之后发生的。该公司受到了充满挑战的生物技术支出格局以及该行业特有的客户不规则订单模式的影响。
Maravai Lifesciences第三季度的业绩低于预期，与预期相比，这两个板块的表现均落后。该公司表示，研究/发现需求下降，没有大量的临时订单，并且几项GMP计划的时间安排已推迟到2025年。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
